Dual antiplatelet therapy effective: MASTER DAPT Trial
Fatal heart diseases are most commonly caused by formation of clots in major blood vessels, its a serious risk that needs to be managed immediately. Antiplatelet medicines can stop blood clots from forming. Anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation. Efficacy of anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation.
Abbreviated antiplatelet therapy was non-inferior to standard antiplatelet therapy with regard to net adverse clinical events reveals the MASTER DAPT trial. The trial evaluated abbreviated antiplatelet therapy compared with standard antiplatelet therapy among patients who underwent percutaneous coronary intervention (PCI) with a biodegradable-polymer sirolimus-eluting stent.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.